Crossmark

Engineered long-acting Irisin-albumin binding domain fusion protein for enhanced anti-inflammatory efficacy in lipopolysaccharide-induced systemic inflammation

Crossref DOI link: https://doi.org/10.1038/s42003-025-09000-z

Published Online: 2025-11-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Jicun

Zhang, Yujie

Wang, Xinwei

Peng, Lei

Ma, Xiaojia

Qiu, Zan

Kang, Zirui

Zheng, Fangyuan

Zhang, Xiaoyu

Song, Mengyuan

Du, Jia

Shi, Yuan

Yu, Lie https://orcid.org/0009-0005-3666-7063
Gu, Chenxi https://orcid.org/0009-0007-2500-7531
Shi, Jianxiang https://orcid.org/0000-0002-4346-3895
Funding

Funding for this research was provided by:

the Project of Basic Research Fund of Henan Institute of Medical and Pharmaceutical Sciences

the Medical Science and Technology Research Project of Henan Province
License Information

Text and Data Mining valid from 2025-11-17

Version of Record valid from 2025-11-17
More Information

Article History

Received: 24 April 2025

Accepted: 3 October 2025

First Online: 17 November 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below